Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06174103
Other study ID # CP-0001
Secondary ID
Status Not yet recruiting
Phase N/A
First received
Last updated
Start date March 2024
Est. completion date December 2026

Study information

Verified date December 2023
Source BiVACOR Inc.
Contact Angela Parsons
Phone 562-732-4272
Email angela.parsons@bivacor.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the feasibility of using the BiVACOR Total Artificial Heart (TAH) System to support adult patients with severe biventricular heart failure, or univentricular heart failure in which left ventricular assist device (LVAD) support is not recommended, who require mechanical circulatory support to sustain life. The BiVACOR TAH System is intended for use as a bridge to transplant (BTT). Feasibility will be assessed by evaluating safety and performance of the BiVACOR TAH System in study subjects.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 5
Est. completion date December 2026
Est. primary completion date August 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Patient has severe, irreversible biventricular heart failure and is eligible for biventricular mechanical circulatory support based on the International Society of Heart and Lung Transplantation (ISHLT) guidelines or has univentricular heart failure in which LVAD support is not recommended. ISHLT Guidelines for Biventricular Support: 1. Biventricular failure with at least two of the following hemodynamic and/or echocardiographic measurements. 1. Right ventricular ejection fraction (RVEF) = 30% 2. Right ventricular stroke work index (RVSWI) = 0.25 g/m/beat/m2 3. Tricuspid annular plane systolic excursion (TAPSE) = 14 mm 4. Right ventricular (RV) to left ventricular (LV) end-diastolic diameter ratio > 0.72 5. Central venous pressure (CVP) > 15mmHg 6. CVP to pulmonary capillary wedge pressure (PCWP) ratio > 0.63 7. Tricuspid insufficiency grade 4 8. Pulmonary artery pressure index (PAPi) < 2 2. Treatment-refractory recurrent and sustained ventricular tachycardia or ventricular fibrillation in the presence of untreatable arrhythmogenic pathologic substrate. 3. Heart failure due to restrictive or constrictive physiology (e.g., hypertrophic cardiomyopathy, cardiac amyloidosis/senile or other infiltrative heart disease). - Patient is categorized as Intermacs Patient Profile Classification 2 or 3. - Patient is classified as NYHA Class IV. - Patient has a left ventricular ejection fraction (LVEF) = 25%. - Patient is inotrope dependent, OR has a cardiac index (CI) = 2.2 L/min/m2 without inotropes if inotropes are contraindicated (e.g., restrictive or constrictive heart failure), and meets one of the following criteria: 1. Is on optimal medical management (OMM), based on current heart failure practice guidelines for at least 45 out of the last 60 days and is failing to respond or is not able to tolerate OMM; or 2. Has advanced heart failure for at least 14 days and is dependent on an intra-aortic balloon pump (IABP) or similar temporary mechanical circulatory support device (MCSD) for at least seven days. - Patient is eligible for cardiac transplantation as determined by the implanting center. - Patient has adequate room in the chest as determined by 3-D imaging or other standard clinical assessments. - Patient has read and understands the informed consent form (ICF) and has voluntarily provided informed consent. Exclusion Criteria: - Patient has contraindications to anticoagulation or antiplatelet therapies. - Patient has coagulopathy defined by a platelet count < 50 k/µl. - Patient has insufficient space in the chest to accommodate the BiVACOR pump. - Patient has a body mass index (BMI) = 35 kg/m2. - Patient is highly pre-sensitized prior to pump implantation. - Patient is unconscious and unresponsive. - Patient is on pre-implant extracorporeal membrane oxygenation (ECMO) for > 7 days. - Patient is on pre-implant temporary MCSD for more than 21 days [e.g., Intra-aortic balloon pump (IABP), Impella, CentriMag, etc.] unless ambulatory and free from adverse effects associated with the MCSD. - Patient is implanted with durable mechanical circulatory support (LVAD or RVAD). - Patient experienced cerebrovascular accident (CVA) within three months of eligibility evaluation. - Patient has severe end-organ dysfunction as evidenced by: 1. Total bilirubin > 4.0 mg/dL or cirrhosis confirmed by imaging or positive biopsy, and/or 2. Glomerular filtration rate (GFR) < 30 mL/min/1.73 m2 or renal replacement therapy dependence. - Patient has severe chronic obstructive pulmonary disease (COPD) or restrictive lung disease requiring home oxygen. - Patient has primary pulmonary hypertension = 8 Wood units. - Patient has severe systemic light-chain amyloidosis. - Patient has been diagnosed with severe cardiac cachexia or irreversible frailty. - Patient has diabetes with advanced diabetic neuropathy with accompanying skin ulceration. - Patient has a blood-borne infection within seven days of eligibility evaluation. Positive blood cultures reflective of contaminants (e.g., Staphylococcus epidermidis) will not be considered an exclusion. - Patient is pregnant or planning pregnancy. - Patient has a co-morbidity or illness that would limit survival to less than two years. - Patient has a current drug and/or alcohol addiction or known substance abuse. - Patient has insufficient social support or a history of non-compliance with medical instructions as determined by the Investigator. - Patient is participating in another clinical trial that may impact or confound the results of the BiVACOR TAH EFS.

Study Design


Related Conditions & MeSH terms


Intervention

Device:
BiVACOR TAH System
The BiVACOR pump is an implantable rotary biventricular blood pump that uses magnetic levitation technology for increased durability to replace both ventricles of a failing heart. The device is intended to replace the diseased heart in patients suffering from heart failure to bridge the time to heart transplant.

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
BiVACOR Inc.

Outcome

Type Measure Description Time frame Safety issue
Primary Feasibility Endpoint Survival on the original BiVACOR pump 6 months or time of heart transplant (if prior to 6 months post pump implant)
Primary Safety Endpoint Evaluation of the safety of the BiVACOR TAH System using Intermacs adverse event (AE) terms and definitions (Intermacs Manual of Operations Version 5). Through 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT05654272 - Development of CIRC Technologies
Recruiting NCT05196659 - Collaborative Quality Improvement (C-QIP) Study N/A
Recruiting NCT05650307 - CV Imaging of Metabolic Interventions
Active, not recruiting NCT05896904 - Clinical Comparison of Patients With Transthyretin Cardiac Amyloidosis and Patients With Heart Failure With Reduced Ejection Fraction N/A
Completed NCT05077293 - Building Electronic Tools To Enhance and Reinforce Cardiovascular Recommendations - Heart Failure
Recruiting NCT05631275 - The Role of Bioimpedance Analysis in Patients With Chronic Heart Failure and Systolic Ventricular Dysfunction
Enrolling by invitation NCT05564572 - Randomized Implementation of Routine Patient-Reported Health Status Assessment Among Heart Failure Patients in Stanford Cardiology N/A
Enrolling by invitation NCT05009706 - Self-care in Older Frail Persons With Heart Failure Intervention N/A
Recruiting NCT04177199 - What is the Workload Burden Associated With Using the Triage HF+ Care Pathway?
Terminated NCT03615469 - Building Strength Through Rehabilitation for Heart Failure Patients (BISTRO-STUDY) N/A
Recruiting NCT06340048 - Epicardial Injection of hiPSC-CMs to Treat Severe Chronic Ischemic Heart Failure Phase 1/Phase 2
Recruiting NCT05679713 - Next-generation, Integrative, and Personalized Risk Assessment to Prevent Recurrent Heart Failure Events: the ORACLE Study
Completed NCT04254328 - The Effectiveness of Nintendo Wii Fit and Inspiratory Muscle Training in Older Patients With Heart Failure N/A
Completed NCT03549169 - Decision Making for the Management the Symptoms in Adults of Heart Failure N/A
Recruiting NCT05572814 - Transform: Teaching, Technology, and Teams N/A
Enrolling by invitation NCT05538611 - Effect Evaluation of Chain Quality Control Management on Patients With Heart Failure
Recruiting NCT04262830 - Cancer Therapy Effects on the Heart
Completed NCT06026683 - Conduction System Stimulation to Avoid Left Ventricle Dysfunction N/A
Withdrawn NCT03091998 - Subcu Administration of CD-NP in Heart Failure Patients With Left Ventricular Assist Device Support Phase 1
Recruiting NCT05564689 - Absolute Coronary Flow in Patients With Heart Failure With Reduced Ejection Fraction and Left Bundle Branch Block With Cardiac Resynchronization Therapy